Insider Buying: NovaBay Pharmaceuticals, Inc. (NYSE:NBY) Major Shareholder Buys $45,945.25 in Stock

Posted by Michael Walen on Apr 18th, 2025

NovaBay Pharmaceuticals, Inc. (NYSE:NBY – Get Free Report) major shareholder Poplar Point Capital Partners bought 70,685 shares of the firm’s stock in a transaction on Friday, January 31st. The stock was purchased at an average cost of $0.65 per share, for a total transaction of $45,945.25. Following the completion of the acquisition, the insider now owns 620,685 shares in the company, valued at approximately $403,445.25. This trade represents a 12.85 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Poplar Point Capital Partners also recently made the following trade(s):

On Monday, January 27th, Poplar Point Capital Partners purchased 31,703 shares of NovaBay Pharmaceuticals stock. The shares were purchased at an average price of $0.69 per share, for a total transaction of $21,875.07.
On Thursday, February 20th, Poplar Point Capital Partners acquired 1,836 shares of NovaBay Pharmaceuticals stock. The shares were purchased at an average price of $0.63 per share, with a total value of $1,156.68.
On Tuesday, February 18th, Poplar Point Capital Partners bought 3,222 shares of NovaBay Pharmaceuticals stock. The stock was acquired at an average cost of $0.66 per share, for a total transaction of $2,126.52.
On Monday, February 3rd, Poplar Point Capital Partners purchased 2,597 shares of NovaBay Pharmaceuticals stock. The shares were acquired at an average cost of $0.64 per share, with a total value of $1,662.08.
On Friday, March 7th, Poplar Point Capital Partners acquired 102 shares of NovaBay Pharmaceuticals stock. The stock was acquired at an average cost of $0.55 per share, for a total transaction of $56.10.
On Tuesday, March 4th, Poplar Point Capital Partners bought 4,000 shares of NovaBay Pharmaceuticals stock. The stock was acquired at an average price of $0.58 per share, for a total transaction of $2,320.00.
On Thursday, February 27th, Poplar Point Capital Partners bought 385 shares of NovaBay Pharmaceuticals stock. The stock was bought at an average cost of $0.61 per share, with a total value of $234.85.
On Tuesday, February 25th, Poplar Point Capital Partners purchased 25,033 shares of NovaBay Pharmaceuticals stock. The shares were bought at an average cost of $0.62 per share, for a total transaction of $15,520.46.
On Friday, March 14th, Poplar Point Capital Partners acquired 25,511 shares of NovaBay Pharmaceuticals stock. The stock was bought at an average cost of $0.63 per share, with a total value of $16,071.93.
On Wednesday, March 12th, Poplar Point Capital Partners bought 11,837 shares of NovaBay Pharmaceuticals stock. The stock was bought at an average price of $0.62 per share, for a total transaction of $7,338.94.

NovaBay Pharmaceuticals Price Performance

NovaBay Pharmaceuticals stock opened at $0.60 on Friday. The business has a 50 day moving average of $0.60 and a 200-day moving average of $0.63. The company has a market capitalization of $3.49 million, a P/E ratio of -0.01 and a beta of 0.90. NovaBay Pharmaceuticals, Inc. has a 1 year low of $0.36 and a 1 year high of $9.08.

Wall Street Analysts Forecast Growth

Separately, StockNews.com began coverage on NovaBay Pharmaceuticals in a research note on Friday. They issued a “hold” rating for the company.

Read Our Latest Research Report on NBY

About NovaBay Pharmaceuticals

(Get Free Report)

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.